$ENTA
ENANTA PHARMACEUTICALS INC

2019 Q1 Form 10-Q Financial Statement

#000156459019018517 Filed on May 10, 2019

View on sec.gov

Income Statement

Concept 2019 Q1 2018 Q1
Revenue $39.63M $44.05M
YoY Change -10.03% 391.67%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.780M $5.710M
YoY Change 18.74% 4.58%
% of Gross Profit
Research & Development $34.16M $21.48M
YoY Change 59.03% 65.18%
% of Gross Profit
Depreciation & Amortization $800.0K $610.0K
YoY Change 31.15% 15.09%
% of Gross Profit
Operating Expenses $40.94M $27.19M
YoY Change 50.57% 109.09%
Operating Profit -$1.304M
YoY Change
Interest Expense $2.245M $1.077M
YoY Change 108.45% 13362.5%
% of Operating Profit
Other Income/Expense, Net $2.245M $1.066M
YoY Change 110.6% 94.17%
Pretax Income $941.0K $17.93M
YoY Change -94.75% -300.12%
Income Tax -$3.204M $5.370M
% Of Pretax Income -340.49% 29.96%
Net Earnings $4.145M $12.56M
YoY Change -66.99% -332.84%
Net Earnings / Revenue 10.46% 28.5%
Basic Earnings Per Share $0.21 $0.65
Diluted Earnings Per Share $0.20 $0.61
COMMON SHARES
Basic Shares Outstanding 19.55M 19.21M
Diluted Shares Outstanding 21.08M 20.60M

Balance Sheet

Concept 2019 Q1 2018 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $370.2M $256.7M
YoY Change 44.22% 46.18%
Cash & Equivalents $106.6M $67.53M
Short-Term Investments $264.1M $189.8M
Other Short-Term Assets $14.10M $4.900M
YoY Change 187.76% -19.67%
Inventory
Prepaid Expenses
Receivables $39.60M $44.00M
Other Receivables $0.00 $0.00
Total Short-Term Assets $423.8M $305.7M
YoY Change 38.63% 60.4%
LONG-TERM ASSETS
Property, Plant & Equipment $11.50M $8.616M
YoY Change 33.47% 1.06%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $16.50M $32.20M
YoY Change -48.76% -50.69%
Other Assets $9.800M $8.200M
YoY Change 19.51% -43.45%
Total Long-Term Assets $37.80M $49.00M
YoY Change -22.86% -44.55%
TOTAL ASSETS
Total Short-Term Assets $423.8M $305.7M
Total Long-Term Assets $37.80M $49.00M
Total Assets $461.6M $354.7M
YoY Change 30.14% 27.15%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $8.900M $4.700M
YoY Change 89.36% 15.88%
Accrued Expenses $11.60M $7.000M
YoY Change 65.71% 37.31%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $20.50M $17.12M
YoY Change 19.76% 86.99%
LONG-TERM LIABILITIES
Long-Term Debt $1.900M $1.900M
YoY Change 0.0% 216.67%
Other Long-Term Liabilities $3.249M $2.300M
YoY Change 41.26% -2.34%
Total Long-Term Liabilities $3.249M $4.200M
YoY Change -22.64% 78.34%
TOTAL LIABILITIES
Total Short-Term Liabilities $20.50M $17.12M
Total Long-Term Liabilities $3.249M $4.200M
Total Liabilities $25.37M $21.30M
YoY Change 19.1% 64.52%
SHAREHOLDERS EQUITY
Retained Earnings $147.5M
YoY Change
Common Stock $288.7M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $436.2M $333.4M
YoY Change
Total Liabilities & Shareholders Equity $461.6M $354.7M
YoY Change 30.13% 27.15%

Cashflow Statement

Concept 2019 Q1 2018 Q1
OPERATING ACTIVITIES
Net Income $4.145M $12.56M
YoY Change -66.99% -332.84%
Depreciation, Depletion And Amortization $800.0K $610.0K
YoY Change 31.15% 15.09%
Cash From Operating Activities $30.09M -$7.580M
YoY Change -496.97% 151.83%
INVESTING ACTIVITIES
Capital Expenditures -$2.510M -$760.0K
YoY Change 230.26% 31.03%
Acquisitions
YoY Change
Other Investing Activities $3.830M $7.210M
YoY Change -46.88% 202.94%
Cash From Investing Activities $1.320M $6.460M
YoY Change -79.57% 258.89%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 260.0K -10.00K
YoY Change -2700.0% -95.24%
NET CHANGE
Cash From Operating Activities 30.09M -7.580M
Cash From Investing Activities 1.320M 6.460M
Cash From Financing Activities 260.0K -10.00K
Net Change In Cash 31.67M -1.130M
YoY Change -2902.65% -20.42%
FREE CASH FLOW
Cash From Operating Activities $30.09M -$7.580M
Capital Expenditures -$2.510M -$760.0K
Free Cash Flow $32.60M -$6.820M
YoY Change -578.01% 180.66%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q1 enta Non Convertible Preferred Stock Liabilities
NonConvertiblePreferredStockLiabilities
1628000
CY2019Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3249000
CY2019Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.20
CY2018Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.61
CY2019Q1 us-gaap Liabilities
Liabilities
25368000
CY2019Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-3204000
CY2018Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5370000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
4145000
CY2019Q1 us-gaap Common Stock Value
CommonStockValue
197000
CY2019Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
288512000
CY2019Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-12000
CY2019Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
147513000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
436210000
CY2019Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
461578000
CY2019Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2019Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2019Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19669000
CY2019Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19669000
CY2018Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
44049000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
109517000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
82158000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
69033000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
39446000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13932000
CY2019Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2245000
CY2018Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1066000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4130000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2026000
CY2019Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
941000
CY2018Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
17925000
CY2017Q3 us-gaap Stockholders Equity
StockholdersEquity
301676000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
2213000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-110000
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
333402000
CY2018Q4 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1161000
CY2018Q4 us-gaap Net Income Loss
NetIncomeLoss
26011000
CY2018Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.65
CY2017Q4 us-gaap Net Income Loss
NetIncomeLoss
11693000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
317579000
CY2018Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1770000
CY2018Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-1756000
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3590000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
426835000
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4466000
CY2019Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-4188000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4707000
us-gaap Profit Loss
ProfitLoss
30156000
us-gaap Share Based Compensation
ShareBasedCompensation
10550000
us-gaap Share Based Compensation
ShareBasedCompensation
7710000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1482000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1200000
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-800000
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
2791000
enta Premium On Marketable Securities
PremiumOnMarketableSecurities
1000
CY2019Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19549000
CY2018Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19206000
CY2019Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21084000
CY2018Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20601000
CY2019Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
245000
CY2019Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
245000
CY2018Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-336000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
386000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-682000
CY2018Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
-128000
CY2017Q4 enta Stock Issued During Period Value Stock Options And Warrants Exercised
StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised
436000
enta Premium On Marketable Securities
PremiumOnMarketableSecurities
243000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
99721000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
104986000
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
5627000
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
2207000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
4188000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1757000
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
39000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1397000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
411000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
42128000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1251000
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
42000
CY2018Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
64510000
CY2017Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
66283000
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
106638000
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
67534000
us-gaap Income Taxes Paid
IncomeTaxesPaid
9955000
us-gaap Income Taxes Paid
IncomeTaxesPaid
9883000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1598000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
111000
us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
41000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-37000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
84000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-27574000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
33435000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
9598000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1369000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2886000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
565000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1259000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-939000
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-1388000
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-3918000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
396000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
236000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
60340000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3169000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
271712000
CY2018Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
593000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to,&#160;<font style="Background-color:#FFFFFF;">management&#8217;s judgments with respect to its revenue arrangements; valuation of stock-based awards; the accrual of research and development expenses, and the accounting for income taxes, including uncertain tax positions and the valuation of net deferred tax assets.&#160;</font>Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from the Company&#8217;s estimates.</p>
us-gaap Year Founded
YearFounded
1995
dei Entity Incorporation State Country Name
EntityIncorporationStateCountryName
Delaware
CY2019Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
380763000
CY2019Q1 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
1628000
CY2018Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
323227000
CY2018Q3 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
1628000
enta Fair Value Measurements Inter Transfers Between Levels
FairValueMeasurementsInterTransfersBetweenLevels
0
enta Fair Value Measurements Inter Transfers Between Levels
FairValueMeasurementsInterTransfersBetweenLevels
0
CY2019Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
280702000
CY2019Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
78000
CY2019Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
143000
CY2019Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
280637000
CY2018Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
261791000
CY2018Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000
CY2018Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
575000
CY2018Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
261217000
CY2019Q1 enta Accrued Preclinical And Clinical Expenses Current
AccruedPreclinicalAndClinicalExpensesCurrent
5530000
CY2018Q3 enta Accrued Preclinical And Clinical Expenses Current
AccruedPreclinicalAndClinicalExpensesCurrent
3617000
CY2019Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1720000
CY2018Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3274000
CY2019Q1 enta Accrued Liabilities Manufacturing
AccruedLiabilitiesManufacturing
2695000
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1459000
CY2018Q3 enta Accrued Liabilities Manufacturing
AccruedLiabilitiesManufacturing
1901000
CY2019Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
742000
CY2018Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
507000
CY2019Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
920000
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1089000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
537000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
197000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
32000
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2932000
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2932000
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1722000
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
36.65
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
82.21
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
28.59
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
70.59
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
45.17
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
45.17
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
34.47
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y1M6D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y2M12D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y2M12D
CY2019Q1 us-gaap Liability For Uncertain Tax Positions Noncurrent
LiabilityForUncertainTaxPositionsNoncurrent
1922000
CY2018Q3 us-gaap Liability For Uncertain Tax Positions Noncurrent
LiabilityForUncertainTaxPositionsNoncurrent
1792000
CY2019Q1 us-gaap Accrued Rent Noncurrent
AccruedRentNoncurrent
842000
CY2018Q3 us-gaap Accrued Rent Noncurrent
AccruedRentNoncurrent
593000
CY2019Q1 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
249000
CY2018Q3 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
293000
CY2019Q1 us-gaap Asset Retirement Obligations Noncurrent
AssetRetirementObligationsNoncurrent
236000
CY2018Q3 us-gaap Asset Retirement Obligations Noncurrent
AssetRetirementObligationsNoncurrent
217000
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2624000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y1M6D
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
129115000
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
148329000
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
148329000
CY2019Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
105171000
CY2019Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4707000
CY2018Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3590000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10550000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7710000
CY2019Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
44379000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y7M6D
CY2019Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1535000
CY2018Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1395000
CY2019Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
784000
CY2018Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
46000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
694000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
449000
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.017
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.271
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
enta Tax Cuts And Jobs Act Of2017 Change In Tax Rate Income Tax Expense Benefit
TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit
3859000
CY2019Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1922000
CY2018Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1792000
enta Number Of Leases
NumberOfLeases
2
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
1246000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
1013000
CY2019Q1 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
608000
CY2018Q3 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
608000

Files In Submission

Name View Source Status
0001564590-19-018517-index-headers.html Edgar Link pending
0001564590-19-018517-index.html Edgar Link pending
0001564590-19-018517.txt Edgar Link pending
0001564590-19-018517-xbrl.zip Edgar Link pending
enta-10q_20190331.htm Edgar Link pending
enta-20190331.xml Edgar Link completed
enta-20190331.xsd Edgar Link pending
enta-20190331_cal.xml Edgar Link unprocessable
enta-20190331_def.xml Edgar Link unprocessable
enta-20190331_lab.xml Edgar Link unprocessable
enta-20190331_pre.xml Edgar Link unprocessable
enta-ex102_12.htm Edgar Link pending
enta-ex103_11.htm Edgar Link pending
enta-ex104_166.htm Edgar Link pending
enta-ex105_165.htm Edgar Link pending
enta-ex311_6.htm Edgar Link pending
enta-ex312_8.htm Edgar Link pending
enta-ex321_7.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g5czb3pfeskd000001.jpg Edgar Link pending
ga0yyqd3rk4w000001.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending